Perrigo (PRGO) vs Vera Therapeutics (VERA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Vera Therapeutics (VERA) has outperformed Perrigo (PRGO) over the past year, losing 1.8% versus a loss of 32.9%. Over five years, VERA leads with a +101.5% price change compared with -67.5% for PRGO. Vera Therapeutics is the larger company by market cap ($2.18 billion vs $2.01 billion), about 1.1 times the size.
Perrigo pays a dividend yielding 7.97%, while Vera Therapeutics does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PRGO | VERA |
|---|---|---|
| Share price | $14.55 | $30.25 |
| Market cap | $2.01B | $2.18B |
| 1-day change | +3.93% | +2.82% |
| YTD return | +4.53% | -40.26% |
| 1-year return | -32.89% | -1.79% |
| 5-year return | -67.46% | +101.53% |
| Forward P/E | 6.07 | — |
| EPS (TTM) | $-12.28 | $-5.87 |
| Dividend yield | 7.97% | 0.00% |
| Annual dividend | $1.16 | $0.00 |
| 52-week high | $22.02 | $56.05 |
| 52-week low | $9.23 | $23.05 |
| Distance from 52-week high | -33.92% | -46.03% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +13.40% | +156.20% |
| Average volume | 2.81M | 2.24M |
| Shares outstanding | 138.37M | 72.06M |
| Employees | 8,100 | 361 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VERA has outperformed PRGO by 31.1 percentage points over the past year.
- Perrigo offers a meaningfully higher dividend yield (7.97% vs 0.00%).
About Perrigo
PRGO stock →Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 8,100 employees
About Vera Therapeutics
VERA stock →Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 361 employees
PRGO vs VERA FAQ
Which is bigger, Perrigo or Vera Therapeutics?
Vera Therapeutics (VERA) is larger, with a market capitalization of $2.18B compared with $2.01B for Perrigo (PRGO).
Which stock has performed better over the past year, PRGO or VERA?
VERA returned -1.79% over the past 12 months, compared with -32.89% for PRGO (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Perrigo or Vera Therapeutics?
Perrigo pays a dividend yielding 7.97%, while Vera Therapeutics does not currently pay a regular dividend.
Are Perrigo and Vera Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.